• Skip to content
  • Skip to primary sidebar
Veloxis
  • Home
  • Company
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents
  • Products
    • Our Technology
    • ENVARSUS XR
  • News & Releases
  • Careers
  • Contact Us

Veloxis Pharmaceuticals: Major Shareholder Notifications

January 15, 2020

Company Release no. 4/2020

PDF Version

To: NASDAQ Copenhagen A/S

Copenhagen, Denmark, 15 January 2020

Veloxis Pharmaceuticals: Major Shareholder Notifications

Veloxis Pharmaceuticals A/S (OMX: VELO) (“Veloxis”) hereby announces that it has received major shareholder notifications pursuant to chapter 7 of Consolidated act no. 931 of 06 September 2019 on Capital Markets, as amended (the “Capital Markets Act”). Pursuant to section 30 of the Capital Markets Act, these major shareholder notifications are attached to this announcement.

For more information, please contact:

Craig A. Collard             Ira Duarte
CEO                              CFO

Phone:                         +1 919-591-3090
Email:                          IR@Veloxis.com

This announcement has been prepared both in English and Danish. In the event of any discrepancies between the English and Danish version, the English version shall prevail.

Attachments:

Announcement from Novo Fonden and Novo Holdings A/S
Announcement from Lundbeckfond Invest A/S

About Veloxis

Veloxis is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company’s unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

Disclaimer

The Offer is made neither directly nor indirectly in any jurisdiction where this would constitute a violation of the legislation within the jurisdiction in question. This announcement and other documents regarding the Offer must not be sent, forwarded or distributed in any other way within a jurisdiction where this would constitute a violation of legislation within said jurisdiction, including in particular in Canada, Japan, Australia or South Africa. This announcement does not constitute an offer or invitation to sell or buy shares in Veloxis. The Offer is made solely on the basis of the offer document prepared and published by Asahi Kasei Pharma Denmark which contains the complete terms and conditions of the Offer. Shareholders and warrant holders in Veloxis are encouraged to read the offer document, the board statement and any associated documents as these contain important information on the Offer.

The Offer is being made in the United States of America in accordance with Section 14(e) of, and Regulation 14E promulgated under, the U.S. Securities Exchange Act of 1934, as amended (the ”Exchange Act”), subject, with respect to the offer to purchase outstanding shares, to the exemption provided by Rule 14d-1(c) under the Exchange Act and otherwise in accordance with the requirements of Danish law. Pursuant to one or more exemptions provided in Rule 14e-5(b) of the Exchange Act, Asahi Kasei Pharma Denmark or its nominees, or its brokers (acting as agents of Asahi Kasei Pharma Denmark or in a similar capacity), may, from time to time, purchase or make arrangements to purchase Veloxis shares and warrants outside of the United States, other than pursuant to the Offer during the period where the Offer remains open for acceptance.

Attachments

  • 2020.01.15 US – Major Shareholder Notifications
  • Major Shareholder Notification – Novo Nordisk Fonden (Novo Holdings)
  • Major Shareholder Notification – Lundbeckfond Invest A/S

Primary Sidebar

Company

  • Overview
  • Management Team
  • Board of Directors

News & Releases

  • Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program
    Jun 18, 2020
  • Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020
    Feb 17, 2020
  • Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S’ Request for Delisting of its Shares from Nasdaq Copenhagen A/S
    Jan 29, 2020

Read More

©2018 All rights reserved. Veloxis Pharmaceuticals, Inc. ENV-18-061.1 06/18

info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET

©2018 All rights reserved. Veloxis Pharmaceuticals, Inc. ENV-18-065.1 06/18

info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET

Sitemap | Contact | Privacy Policy | Disclaimer

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.